Strategies to overcome treatment resistance in pleural mesothelioma patients will likely be based around combination immunotherapies, including alternative checkpoint inhibitors to those acting on the PD- 1/PD-L1 and CTLA- 4 axes [126], angiogenesis inhibitors [117, 127], and chemotherapy [128]. This evidence concerns the gene RPL17 and pleural mesothelioma.